Abl Bio Inc.

I-Mab Biopharma US Limited

Jaeho Jung

Sang Hoon Lee

Eunsil Sung

Dongin Kim

Lei Fang

Juhee Kim

Yangsoon Lee

Eunyoung Park

Yeunju Kim

Byungje Sung

Hyejin Chung

Wenqing Jiang

Youngdon Pak

Jinhyung Ahn

Yong-Gyu Son

Jaehyun Eom

Jiseon Yoo

Jinwon Jung

Sungwon An

Weon-Kyoo You

Seung-Jae Lee

Tae Kyung Kim

Bora Lee

Kyungjin Park

Donghoon Yeom

Daehae Song

Minji Park

Eunjung Kim

Seawon Ahn

Uijung Jung

Hyoju Choi

YoungKwang Kim

Weonkyoo You

Min Sun Choi

Yoseob Lee

Yonggyu Son

Yeun Ju Kim

The present disclosure provides an anti-PD-L1/anti-4-1BB bispecific antibody capable to effectively block the interactions between PD-L1 and its receptor PD-1 and between 4-1BB and its ligand. The bispecific antibody may have high binding affinity to both of a PD-L1 protein and a 4-1BB protein.

Anti-PD-L1/anti-4-1BB bispecific antibodies and uses thereof

The present disclosure provides an anti-PD-L1/anti-LAG3 bispecific antibody capable to effectively block the interactions between PD-L1 and its receptor PD-1 and between LAG3 and its ligand (e.g., a MHC class II molecule and FGL1). The bispecific antibody may have high binding affinity to both of a PD-L1 protein (e.g., a human PD-L1 protein) and a LAG3 protein (e.g., a human LAG3 protein). Also provided are antibodies and fragments that have specificity to the PD-L1 or LAG3 protein alone, or antibodies and fragments having additional specificity to one or more other antigens.

Anti-PD-L1/anti-LAG3 bispecific antibodies and uses thereof

The present invention relates to a bi-specific antibody that specifically binds to alpha-synuclein and IGF1R, and use of the bi-specific antibody for treating or diagnosing synucleinopathies associated with alpha-synuclein or alpha-synuclein aggregates. The IGF1R portion of the bi-specific antibody acts as a shuttle to penetrate the blood brain barrier, allowing the alpha-synuclein portion to exert its action in the brain. Further, the half-life of the bi-specific antibody may be extended to maintain efficacy over time.

Bispecific antibody to alpha-synuclein/insulin-like growth factor 1 receptor and use thereof

The disclosure discloses anti α-Syn antibodies preferentially recognizing α-Syn aggregates. The antibodies of the present invention bind to α-Syn aggregates with high affinity and specificity and inhibit accumulation or intercellular transfer of α-Syn aggregates, and thus can be used for detection, diagnosis and/or treatment or prevention of various diseases caused by the accumulation of α-Syn aggregates.

Anti-alpha-synuclein antibodies and uses thereof

Growing community of inventors

Seongnam-si, South Korea

Jaeho Jung